Deutsche Bank Aktiengesellschaft initiated coverage on shares of Eli Lilly and Company (NYSE:LLY – Free Report) in a research report released on Thursday morning, Marketbeat Ratings reports. The brokerage issued a hold rating and a $535.00 price target on the stock.
Other analysts have also recently issued research reports about the company. Citigroup boosted their target price on Eli Lilly and Company from $525.00 to $675.00 and gave the stock a buy rating in a report on Monday, October 23rd. Argus increased their price objective on shares of Eli Lilly and Company from $470.00 to $620.00 and gave the stock a buy rating in a research report on Tuesday, September 5th. StockNews.com raised shares of Eli Lilly and Company from a hold rating to a buy rating in a research report on Friday, November 3rd. HSBC assumed coverage on Eli Lilly and Company in a research report on Friday, July 14th. They issued a buy rating and a $560.00 price objective on the stock. Finally, Wells Fargo & Company upped their target price on Eli Lilly and Company from $615.00 to $650.00 and gave the stock an overweight rating in a research report on Monday, October 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and twenty have issued a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of Moderate Buy and an average target price of $557.00.
Eli Lilly and Company Price Performance
Eli Lilly and Company Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be given a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a dividend yield of 0.76%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and Company’s dividend payout ratio is currently 81.88%.
Insider Buying and Selling at Eli Lilly and Company
In other news, CAO Donald A. Zakrowski sold 670 shares of the firm’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $571.10, for a total value of $382,637.00. Following the transaction, the chief accounting officer now directly owns 4,708 shares in the company, valued at approximately $2,688,738.80. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, CAO Donald A. Zakrowski sold 670 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $571.10, for a total value of $382,637.00. Following the sale, the chief accounting officer now owns 4,708 shares of the company’s stock, valued at approximately $2,688,738.80. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Donald A. Zakrowski sold 600 shares of the company’s stock in a transaction on Monday, August 21st. The stock was sold at an average price of $546.51, for a total value of $327,906.00. Following the transaction, the chief accounting officer now owns 5,378 shares of the company’s stock, valued at $2,939,130.78. The disclosure for this sale can be found here. Insiders sold a total of 536,138 shares of company stock worth $20,881,627,358 over the last 90 days. Insiders own 0.13% of the company’s stock.
Institutional Trading of Eli Lilly and Company
Several hedge funds have recently bought and sold shares of LLY. Thompson Investment Management Inc. bought a new position in Eli Lilly and Company in the 3rd quarter worth approximately $27,000. Retirement Group LLC grew its stake in shares of Eli Lilly and Company by 159.1% in the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after purchasing an additional 35 shares in the last quarter. Legacy Financial Group LLC acquired a new position in shares of Eli Lilly and Company during the third quarter valued at $35,000. Cornerstone Planning Group LLC bought a new position in Eli Lilly and Company in the 2nd quarter valued at about $33,000. Finally, Silicon Valley Capital Partners bought a new stake in shares of Eli Lilly and Company during the 1st quarter worth about $25,000. 81.38% of the stock is currently owned by institutional investors.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
- Five stocks we like better than Eli Lilly and Company
- What Investors Need to Know to Beat the Market
- MarketBeat Week in Review – 11/6 – 11/10
- Stock Market Sectors: What Are They and How Many Are There?
- Data giants MongoDB and Snowflake just got upgraded
- Investing in Agriculture 101: How to Invest in Agriculture
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.